Livzon Pharmaceutical Group Inc Capital Reinvestment Ratio
Livzon Pharmaceutical Group Inc capital reinvestment ratio. Livzon Pharmaceutical Group Inc (000513) has a Capital Reinvestment Ratio of 0.13x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥625.70 Million) in capital expenditures (CN¥78.72 Million). See cash generation quality of Livzon Pharmaceutical Group Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Livzon Pharmaceutical Group Inc (1999–2025)
Capital reinvestment ratio of Livzon Pharmaceutical Group Inc from 1999 to 2025. This chart tracks Livzon Pharmaceutical Group Inc's Capital Reinvestment Ratio across 27 annual periods. See Livzon Pharmaceutical Group Inc (000513) flexibility index to measure the company's free cash flow as a share of total liabilities.
Livzon Pharmaceutical Group Inc Capital Reinvestment Ratio by Year (1999–2025)
Livzon Pharmaceutical Group Inc capital reinvestment ratio by year from 1999 to 2025. For the full cash flow conversion analysis, see 000513 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.18x | CN¥3.18 Billion | CN¥574.14 Million | ▼ -5.6% |
| 2024 | 0.19x | CN¥2.98 Billion | CN¥570.16 Million | ▼ -24.2% |
| 2023 | 0.25x | CN¥3.25 Billion | CN¥820.45 Million | ▼ -25.5% |
| 2022 | 0.34x | CN¥2.77 Billion | CN¥940.15 Million | ▼ -50.7% |
| 2021 | 0.69x | CN¥1.90 Billion | CN¥1.31 Billion | ▲ +129.8% |
| 2020 | 0.30x | CN¥2.16 Billion | CN¥646.98 Million | ▲ +32.9% |
| 2019 | 0.23x | CN¥1.77 Billion | CN¥398.00 Million | ▼ -39.8% |
| 2018 | 0.37x | CN¥1.27 Billion | CN¥474.47 Million | ▲ +67.4% |
| 2017 | 0.22x | CN¥1.32 Billion | CN¥294.15 Million | ▼ -22.4% |
| 2016 | 0.29x | CN¥1.28 Billion | CN¥368.46 Million | ▼ -44.0% |
| 2015 | 0.51x | CN¥927.79 Million | CN¥477.13 Million | ▼ -44.6% |
| 2014 | 0.93x | CN¥717.39 Million | CN¥665.52 Million | ▼ -55.6% |
| 2013 | 2.09x | CN¥439.99 Million | CN¥920.00 Million | ▲ +62.9% |
| 2012 | 1.28x | CN¥593.96 Million | CN¥762.30 Million | ▲ +160.6% |
| 2011 | 0.49x | CN¥708.20 Million | CN¥348.83 Million | ▼ -7.4% |
| 2010 | 0.53x | CN¥633.30 Million | CN¥336.95 Million | ▲ +100.4% |
| 2009 | 0.27x | CN¥494.88 Million | CN¥131.41 Million | ▲ +21.4% |
| 2008 | 0.22x | CN¥345.18 Million | CN¥75.52 Million | ▼ -40.4% |
| 2007 | 0.37x | CN¥248.55 Million | CN¥91.28 Million | ▼ -53.9% |
| 2006 | 0.80x | CN¥226.46 Million | CN¥180.45 Million | ▼ -50.0% |
| 2005 | 1.59x | CN¥161.07 Million | CN¥256.72 Million | ▲ +97.4% |
| 2004 | 0.81x | CN¥181.46 Million | CN¥146.48 Million | ▲ +133.9% |
| 2003 | 0.35x | CN¥300.01 Million | CN¥103.56 Million | ▼ -28.8% |
| 2002 | 0.48x | CN¥213.65 Million | CN¥103.62 Million | ▼ -7.7% |
| 2001 | 0.53x | CN¥155.15 Million | CN¥81.48 Million | ▼ -67.1% |
| 2000 | 1.60x | CN¥38.52 Million | CN¥61.49 Million | ▲ +435.3% |
| 1999 | 0.30x | CN¥246.23 Million | CN¥73.44 Million | — |